


Research Activities Newsletter

May 2021

In the News: Congratulations to the following awardees!



Elizabeth Bartelt, Clinical Assistant Professor, Department of Community Health and Health Behavior, is PI on a transferred award from the Society of Family Planning Research Fund for the research project entitled, *Sexual and Gender Minority Young Adult (16-26) Experiences of Abortion and Seeking Judicial Bypass in the United States*. This study will examine the experiences of sexual and gender minority (SGM) young people who have had at least one abortion.



Jo Freudenheim, SUNY Distinguished Professor, Department of Epidemiology and Environmental Health, is PI on a new award from Windsong Cares Foundation for the project entitled, *Breast Cancer Microbiome Study at Windsong Breast Care*. The project will examine differences by breast cancer subtype and other clinical characteristics and by breast cancer risk factors.



Gregory Wilding, Professor and Chair, Biostatistics, is Co-I on a new award from the National Institute of Allergy and Infectious Diseases/NIH (PI: Jonathan Lovell, Biomedical Engineering) for the project entitled, *Rationally-Designed, Spontaneous-Particleized Pfs48/45 for a Multivalent Malaria Vaccine*. The project seeks to develop a vaccine that will block the transmission of malaria by focusing the immune response towards the same target epitope of a potent monoclonal antibody against Pfs48/45, an antigen candidate, the structure of which was recently solved.



Gregory Homish, Professor and Chair, Department of Community Health and Health Behavior, is Co-PI (with Co-PI: Ken Leonard, Psychiatry) on the T32-training grant entitled *Research Training on Alcohol Etiology and Treatment*. The competitive renewal award provides five additional years of funding (Years 21 through 25), from the National Institute on Alcohol Abuse and Alcoholism/NIH.

Dr. Homish also received an administrative supplement from the National Institute of Drug Abuse/NIH for his project entitled, *Substance Use in Reservists: Social and Environmental Influences*. The longitudinal study continues to examine the impact of two military experiences - never being deployed and separation from military – on substance use outcomes for both soldiers and their spouses.



Guan Yu, Assistant Professor, Biostatistics, is Co-I on a new award from the National Institute of Biomedical Imaging and Bioengineering/NIH (Jun Xia, PI, Biomedical Engineering), for the research project entitled, *Development of photoacoustic tomography for non-invasive, label-free imaging of tissue perfusion in chronic wounds*. This project will develop a three-dimensional (3D) wound assessment system using photoacoustic tomography (PAT), a hybrid modality that detects optical absorption in tissue through the photoacoustic effect.

In This Issue

In the News: Congratulations to the Following Awardees	1
Grant Clinic.....	2
NIH Funding Opportunities	
Request for Applications (RFA)	6
Program Announcements Reviews in an Institute (PAR)	12
Program Announcements (PA)	12
Individual Actions for Sustainability	19

Grant Clinic

GENERAL NOTICE

A new Research Space/Venue Questionnaire is now available on the [SPHHP website](#). Investigators who are planning to submit proposals, please complete both the [RAS Questionnaire](#) and [Research Venue/Space Questionnaire](#).

NOT-OD-21-073

REMINDER! Changes to the Biographical Sketch and Other Support Format Page for Due Dates on or after May 25, 2021

Please check the Notice for the Specific changes. A full copy of the updated Biosketch instructions can be found [here](#). Use of the updated format pages will be required for applications and Research Performance Progress Reports (RPPRs) submitted for due dates on or after May 25, 2021. During the transition to the new Biosketch format, NIH will not withdraw applications that include the previous Biosketch format. Beginning with applications submitted on or after January 25, 2022, failure to follow the appropriate Biosketch format may cause NIH to withdraw your application from consideration.

The RAS staff are familiar with the new format and are available to assist you.

NOT-OD-21-114

Notice of Intent to Reissue PAR-18-847 and PAR-18-848

This Notice is to inform the research community that the Office of Disease Prevention and participating NIH Institutes, Centers, and Offices intend to reissue the Funding Opportunity Announcement (FOA) [PAR-18-847](#) "Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied Prevention Research (R01 - Clinical Trial Optional)" and [PAR-18-848](#) "Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied Prevention Research (R21 - Clinical Trial Optional)." The NOSI is expected to be published in June 2021.

NOT-OD-21-113

Notice of Intent to Reissue PAR-18-845 and PAR-18-846

Also being reissued is the Funding Opportunity Announcement (FOA) [PAR-18-845](#) "Electronic Nicotine Delivery Systems (ENDS): Basic Mechanisms of Health Effects (R01 - Clinical Trial Not Allowed)" and [PAR-](#)

18-846 "Electronic Nicotine Delivery Systems (ENDS): Basic Mechanisms of Health Effects (R21 - Clinical Trial Not Allowed)." The NOSI is expected to be published in June 2021.

NOT-HL-21-014

Availability of Frequently Asked Questions (FAQs) for RFA-HL-22-007 and RFA-HL-22-008: Early Intervention to Promote Cardiovascular Health of Mothers and Children (ENRICH) program

The purpose of this Notice is to inform potential applicants that Frequently Asked Questions (FAQs) for Funding Opportunity Announcements (FOAs) [RFA-HL-22-007](#) and [RFA-HL-22-008](#): Early Intervention to Promote Cardiovascular Health of Mothers and Children (ENRICH) program are available at the following link: <https://www.nhlbi.nih.gov/grants-and-training/funding-opportunities/foa-ENRICH-FAQ>. Applicants are strongly encouraged to review the FAQs, which may be updated at any time without additional notice, prior to application submission.

NOT-CA-21-067

Seeking Stakeholder Input on Enhancing Diversity and Inclusion in the Cancer Research Workforce

NCI seeks information and recommendations that will help identify best practices, challenges, resources, and opportunities to enhance diversity and inclusion in the cancer research workforce and promote equity and social justice in the NCI extramural research community, to the extent permitted by law. Responses will be accepted through July 15, 2021. Please limit your response to two pages or less. Responses must be e-mailed to NCI.RFI.DiversityandInclusionWorkforce@nih.gov.

NOTICE OF CHANGES TO FUNDING OPPORTUNITIES

NOT-DA-21-057

Notice of Change to RFA-DA-21-016, "Novel Approaches to Decrease Stigma of Substance Use Disorders in order to Facilitate Prevention, Treatment, and Support During Recovery (R43/R44 - Clinical Trials Optional)"

The purpose of this notice is to inform interested applicants of a change to the Advisory Council Review date to Funding Opportunity Announcement (FOA) [RFA-DA-21-016](#), "Novel Approaches to Decrease Stigma of Substance Use Disorders in order to Facilitate Prevention, Treatment, and Support During Recovery (R43/R44 - Clinical Trials Optional)". **Part 1. Overview Information Key Dates Revised to Read: Advisory Council Review August 2021** All other aspects of this FOA remain unchanged.

NOT-DA-22-015

Notice of NIDA's Participation in NOT- MD-21-008 "Notice of Special Interest (NOSI): Research to Address Vaccine Hesitancy, Uptake, and Implementation among Populations that Experience Health Disparities"

The purpose of this Notice is to inform potential applicants that the National Institute on Drug Abuse (NIDA) will participate, effective immediately in [NOT-MD-21-008](#), Notice of Special Interest (NOSI): Research to Address Vaccine Hesitancy, Uptake, and Implementation among Populations that Experience Health Disparities".

NOTICE OF SPECIAL INTERESTS

If you will be applying under any of the special interest topics listed below, please indicate so, including the NIH Notice number, in the Comments box of the RAS Questionnaire. The RAS staff will ensure that this information is included with the application to NIH.

NOT-CA-21-074

Early-life Factors and Cancer Development Later in Life

This NOSI seeks to further support research on early-life factors and cancer development later in life. Studies proposed in response to this NOSI should focus on human studies, but may incorporate research

using animal models, especially in elucidating mechanisms relevant in humans. **Applicants must include “NOT-CA-21-074” in box 4B of the SF424 R&R form.** This NOSI will expire on March 08, 2024.

[NOT-AA-21-028](#)

Public Policy Effects on Alcohol-, Cannabis-, Tobacco-, and Other Drug-Related Behaviors and Outcomes

This Notice is intended to support innovative research to examine policy effects that have the potential to lead to meaningful changes in public health. Research projects that may be supported include, but are not necessarily limited to: causal analyses of the effects of one or multiple public policies; evaluations of the effectiveness of specific public policies as tools for improving public health through their effects on alcohol-, cannabis-, tobacco-, and other substance-related behaviors and outcomes; studies of disparities in policy effects and the role of policy in exacerbating or potentially reducing health disparities; and research to advance methods and measurement used in studying relationships between public policies and alcohol-, cannabis-, tobacco-, and other substance-related behaviors and outcomes. **Applicants must include “NOT-AA-21-028” in box 4B of the SF424 R&R form.**

[NOT-DA-21-012](#)

Women and Sex/Gender Differences in Drug and Alcohol Abuse/Dependence

The purpose of this Notice is to inform potential applicants of the National Institute on Drug Abuse (NIDA) special interest in grant applications to conduct rigorous basic, translational and/or clinical research to: (1) advance identification of sex and/or gender differences in risk for substance use disorders or the response or medical consequences of alcohol or substance misuse to uncover the mechanisms of those differences, and to conduct translational research on those differences, and (2) advance research specific to women or highly relevant to women. Both preclinical and clinical studies are sought across all areas of drug and alcohol research. **Applicants must include “NOT-DA-21-012” in box 4B of the SF424 R&R form.**

[NOT-CA-21-071](#)

Expanding Cancer Control Research in Persistent Poverty Areas

The purpose of this Notice is to inform potential applicants about the National Cancer Institute (NCI)'s special interest in providing resources to support highly collaborative, multi-disciplinary Program Projects (P01s) that focus on the development and conduct of cancer control research in low-income and/or underserved populations living in persistent poverty (PP) areas. NCI is interested in programs that address the challenges and opportunities related to working in partnership with local clinics and other health or public health-related organizations to enhance the prevention of cancer and delivery of cancer care strategies to reduce the burden of cancer in PP areas. **Applicants must include “NOT-CA-21-071” in box 4B of the SF424 R&R form.** This NOSI will expire on May 08, 2023.

[NOT-DA-21-003](#)

Leveraging Longitudinal Studies in Animal Models to Identify Neural Mechanisms of Vulnerability and Resilience to Substance Use Disorder

NIDA seeks to stimulate research in non-human species aimed at modeling environmental and/or biological risk factors for SUD to elucidate neural and cognitive developmental mechanisms that may mediate, moderate, or predict the effects of these factors on subsequent emergence of SUD-related behaviors. Use of longitudinal designs and developmental-stage-appropriate paradigms are strongly encouraged. **Applicants must include “NOT-DA-21-003” in box 4B of the SF424 R&R form.** This NOSI will expire on September 08, 2024.

[NOT-AG-21-015](#)

Aging-Relevant Behavioral and Social Research on Coronavirus Disease 2019 (COVID-19)

This Notice of Special Interest (NOSI) is to highlight the continuing need for behavioral, psychological, social, and economic research on SARS-CoV-2 and coronavirus disease 2019 (COVID-19). There is a need for ongoing research on the longer-term effects of COVID-19 on the health and well-being of those infected, those caring for the sick, and many others whose lives were disrupted by the pandemic and its associated mitigation and prevention strategies. **Applicants must include “NOT-AG-21-015” in box 4B of the SF424 R&R form.** This NOSI will expire on May 08, 2023.

[NOT-CA-21-031](#)

Understanding the effects of cancer and cancer treatment on aging trajectories and aging outcomes

The purpose of this Notice of Special Interest is to solicit investigator-initiated applications that aim to better understand the effects of a cancer diagnosis and subsequent cancer treatment on aging trajectories and aging outcomes. Investigations in understudied populations, including those that are medically underserved, are encouraged. This notice applies to due dates on or after *March 8, 2021*, and subsequent receipt dates through January 7, 2024. **Applicants must include “NOT-CA-21-031” in box 4B of the SF424 R&R form.** This NOSI will expire on January 08, 2024.

[NOT-DA-21-011](#)

Effects of smoking and vaping on the risk and outcome of COVID-19 infection

The purpose of this notice is to communicate NIDA’s interest in supporting research on **the effects of smoking or vaping tobacco or marijuana on the risk of acquiring COVID-19 and the clinical course of the infection.** This Notice is a reissuance of [NOT-DA-20-084](#). Research applications focusing on individuals who smoke or vape either marijuana and/or tobacco to determine: 1) the risk of contracting a COVID-19 infection, 2) the effects on asymptomatic COVID-19 infected persons, and 3) the course of the COVID-19 infection. **Applicants must include “NOT-DA-21-011” in box 4B of the SF424 R&R form.** This NOSI will expire on September 08, 2024.

[NOT-DA-21-017](#)

Medical Consequences of Smoking & Vaping Drugs of Abuse in Individuals with HIV and COVID-19

NIDA is interested in receiving research applications focusing on individuals with HIV who smoke or vape marijuana, tobacco, cocaine and/or methamphetamine to determine the long-term effects of their use among individuals with HIV and COVID-19. **Applicants must include “NOT-DA-21-017” in box 4B of the SF424 R&R form.** This NOSI will expire on September 08, 2024.

[NOT-MD-21-008](#)

Research to Address Vaccine Hesitancy, Uptake, and Implementation among Populations that Experience Health Disparities

The purpose of this NOSI is to solicit community-engaged research to: 1) evaluate intervention strategies (e.g., expand reach, access) to facilitate vaccination uptake in clinical and community contexts; and 2) address the barriers to increasing reach, access, and uptake of vaccinations among health disparity populations at high risk and likely to experience vaccine hesitancy. Submit applications for this initiative using [PA-20-183](#) & [PA-20-185](#). **Applicants must include “NOT-MD-21-008” in box 4B of the SF424 R&R form.** This NOSI will expire on January 08, 2022.

[NOT-CA-21-008](#)

Availability of Administrative Supplements to Adapt/Repackage Visualization Methods for Enhancing Cancer Moonshot Data

Through funds available from the [Cancer Moonshot Initiative](#), and pursuant to the National Cancer Institute’s (NCI’s) interest in advancing data visualization tools and methods for cancer research, applications are invited, through [PA-20-272](#) in conjunction with this Notice of Special Interest (NOSI), for one-year administrative supplements to support the adaptation and repackaging of existing broad-based visualization methods that have the potential to make Cancer Moonshot-aligned data more explorable and interpretable by the broader cancer research community. Submit applications for this initiative using [PA-20-272](#). **Applicants must include “PA-20-272” in box 4B of the SF424 R&R form.** Applications can be submitted on a rolling basis for possible funding in FY2021, FY2022, and FY2023. This NOSI will expire on November 3, 2022.

[NOT-OD-21-087](#)

Developing and Testing Multilevel Physical Activity Interventions to Improve Health and Well-Being

The Office of Disease Prevention and participating ICOs are issuing this Notice to highlight our interest in encouraging highly innovative and promising translational research to improve our understanding of how to increase and maintain health-enhancing physical activity using multi-level interventions in a wide range of population groups across the lifespan (e.g., including racial and ethnic minorities, children, older adults,

persons with medical/behavioral health conditions, and persons with disabilities). **Applicants must include “NOT-OD-21-087” in box 4B of the SF424 R&R form.** This NOSI will expire on February 16, 2024.

NOT-OD-21-100

Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health

The objective of this NOSI is to encourage research grant applications that address patient adherence to treatment and prevention regimens to promote health outcomes. Applications may address healthcare regimen initiation, implementation, and/or persistence by patients. Descriptive and intervention research may address adherence determinants at one or more levels of ecologic influence, including the patient, caregiver/family, provider, healthcare system, and community levels. **Applicants must include “NOT-OD-21-100” in box 4B of the SF424 R&R form.** This NOSI will expire on June 08, 2024.

NIH Funding Opportunities

NIH Funding Opportunities: Request for Applications (RFA)

JULY DUE DATES

RFA-CA-21-031 (U01 Clinical Trial Required)

Exercise and Nutrition Interventions to Improve Cancer Treatment-Related Outcomes (ENICTO) in Cancer Survivors Consortium

The National Cancer Institute (NCI) seeks to support exercise and/or medical nutrition intervention research designed to improve cancer treatment-related outcomes for therapies delivered with curative or life-extending intent to cancer survivors. Priority will be given to studies with direct clinical relevance and translational potential. Responsive applications will fill a research gap concerning the efficacy of specific exercise and dietary approaches to improve cancer treatment-related outcomes. Awardees will participate in an Exercise and Nutrition to Improve Cancer Treatment-Related Outcomes (ENICTO) in Cancer Survivors Consortium. **Application Due Date:** July 14, 2021.

RFA-DE-22-002 (UG3/UH3 Clinical Trials Optional)

Addressing Social Determinants of Health to Eliminate Oral Health Disparities

Applications in response to this FOA must propose research that involves improving oral health outcomes through addressing or better understanding one or more upstream social determinants of health that operate beyond the individual-level of influence (as indicated in the National Institute on Minority Health and Health Disparities Research or Social-Ecological Model frameworks). Awards made under this FOA will initially support a planning phase (UG3) for up to one year, with possible transition to an implementation phase of up to five years (UH3) for a total of up to six years of funding.

Application Due Date: July 8, 2021.

RFA-TW-21-001 (Collaborative U01 Clinical Trial Optional)

RFA-TW-21-002 (Collaborative U2R Clinical Trial Optional)

Hubs of Interdisciplinary Research and Training in Global Environmental and Occupational Health (GEOHealth)

This FOA solicits applications for research training activities in linked Hubs of Interdisciplinary Research and Training in Global Environmental and Occupational Health (GEOHealth). The overall objective of the GEOHealth program is to support the development of institutions in the Low- or Middle-Income Countries (LMICs) that will serve as regional hubs for collaborative research, data management, research training, curricula and outreach material development, and policy support around high priority local, national, and regional environmental and occupational health threats.

Application Due Date: July 8, 2021.

**[RFA-AI-21-025](#) (R01 Clinical Trial Optional)
Prevention Strategies to End the HIV Epidemic**

The purpose of this FOA is to support projects to improve use of evidence-based HIV prevention interventions among populations in priority areas identified as highly impacted by HIV. Research funded under this FOA will support the goals of the DIAGNOSE and PREVENT pillars of the *Ending the HIV Epidemic: A Plan for America* (EHE) initiative towards reducing HIV incidence. Creative, multidisciplinary approaches are needed to meet the needs of specific populations and localities. **Application Due Date:** July 30, 2021.

AUGUST DUE DATES

**[RFA-TW-21-004](#) (D43 Clinical Trial Optional)
Launching Future Leaders in Global Health (LAUNCH) Research Training Program**

The purpose of this program is to provide opportunities for up to six consortia to develop or expand global health research training programs that meet the following objectives: (1) provide one-year mentored research training for pre-doctoral students from the U.S. and recent post-doctoral and post-professional degree graduates (collectively referred to as trainees) from the U.S. and low- and middle- income countries (LMICs) in global health research at established biomedical and health research institutions and project sites in LMICs, particularly those supported by the NIH; (2) provide training opportunities within broad areas of research relevant to the health priorities of collaborating LMICs and aligned with the scientific priorities across the NIH Institutes, Centers, and Offices; (3) provide the solid scientific research foundation needed for trainees to rigorously develop and conduct research and effectively communicate research findings with increasing independence, with the goal of enhancing the global health research career potential of the trainees; and (4) provide more equitable access to and inclusive participation in this program to diverse populations in the U.S..

Application Due Date: August 20, 2021.

**[RFA-RM-21-016](#) (DP2 Clinical Trial Optional)
NIH Director's New Innovator Award Program**

The NIH Director's New Innovator Award Program supports early-stage investigators of exceptional creativity who propose highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the research workforce. The NIH Director's New Innovator Award Program complements other ongoing efforts by NIH and its Institutes and Centers to fund early-stage investigators.

Application Due Date: August 20, 2021.

**[RFA-DA-22-012](#) (R01 Clinical Trial Optional)
Assessing the Effects of Cannabinoids on HIV-Associated Persistent Inflammation**

The purpose of this Funding Opportunity Announcement (FOA) is to encourage basic science and preclinical research to determine the biological mechanisms underlying 1) the effects of cannabinoids and the endocannabinoid system on HIV-associated persistent inflammation, and 2) its consequent effects on nervous system function. Projects submitted in response to this FOA must include expertise and resources in both areas of HIV/AIDS and addiction science.

Application Due Date: August 05, 2021.

**[RFA-DA-22-001](#) (R43/R44 Clinical Trial Optional)
Mobile Health Solutions to rectify digital inequality in communities affected by drug addiction**

This FOA issued by NIDA, invites eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) grant applications to develop mobile health technologies, including wearables and other digital health enabled technologies, to address existing digital inequalities affecting underserved and vulnerable populations suffering from Substance Use Disorders (SUD).

Application Due Date: August 13, 2021.

[RFA-MD-21-004](#) (R01 Clinical Trial Optional)

Understanding and Addressing the Impact of Structural Racism and Discrimination on Minority Health and Health Disparities

This initiative will support (1) observational research to understand the role of structural racism and discrimination (SRD) in causing and sustaining health disparities, and (2) intervention research that addresses SRD in order to improve minority health or reduce health disparities.

Application Due Date: August 24, 2021.

[RFA-AI-21-024](#) (R01 Clinical Trial Optional)

Multidisciplinary Treatment Approaches to End the HIV Epidemic

The purpose of this Funding Opportunity Announcement (FOA) is to utilize implementation science to develop, implement, and evaluate creative, multidisciplinary approaches to healthcare delivery that more effectively engage and retain individuals in HIV care and treatment so that they achieve durable viral suppression. Research funded under this FOA will support the goals of the DIAGNOSE and TREAT pillars of the *Ending the HIV Epidemic: A Plan for America* (EHE) initiative by seeking to achieve more rapid and sustained viral suppression and improved outcomes for people with HIV through better healthcare engagement.

Application Due Date: August 05, 2021.

SEPTEMBER DUE DATES

[RFA-RM-21-018](#) (DP5 Clinical Trial Optional)

NIH Director's Early Independence Awards

The NIH Director's Early Independence Award supports exceptional junior investigators who wish to pursue independent research soon after completion of their terminal doctoral degree or post-graduate clinical training, thereby forgoing the traditional post-doctoral training period and accelerating their entry into an independent research career.

Application Due Date: September 03, 2021.

[RFA-AG-22-016](#) (R61/R33 Clinical Trial Required)

Mechanism-Focused Research to Promote Adherence to Healthful Behaviors to Prevent Mild Cognitive Impairment (MCI) and Alzheimer's Disease and Related Dementias (AD/ADRD)

This FOA will support pilot research (R61) to identify, measure, and assess the malleability of psychological or interpersonal adherence-relevant targets that, if successful, can transition to an R33 phase for implementation of rigorous, proof-of-concept intervention studies. The transition from the R61 to the R33 phase of the award will be administratively reviewed for and be dependent upon successful completion of the go/no-go criteria specified for the R61 phase.

Application Due Date: September 05, 2021.

[RFA-RM-21-015](#) (DP1 Clinical Trial Optional)

NIH Director's Pioneer Award Program

The NIH Director's Pioneer Award Program supports individual scientists of exceptional creativity who propose highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. To be considered pioneering, the proposed research must reflect substantially different scientific directions from those already being pursued in the investigator's research program or elsewhere.

Application Due Date: September 10, 2021.

OCTOBER DUE DATES

[RFA-DA-22-005](#) (R21 Clinical Trial Not Allowed)

[RFA-DA-22-007](#) (R01 Clinical Trial Not Allowed)

[RFA-DA-22-024](#) (R01 Basic Experimental Studies with Humans Required)

[RFA-DA-22-030](#) (R21 Basic Experimental Studies with Humans Required)

Mechanistic studies on the impact of social inequality on the substance use trajectory

This funding opportunity announcement invites mechanistic studies on the impact of social inequality on the brain and on the substance use trajectory. Applications investigating relevant mechanisms at the behavioral, cognitive, neurocircuitry, cellular, genetics, and epigenetics levels are encouraged.

Application Due Date: October 14, 2021.

[RFA-AG-22-009](#) (R25 Clinical Trial Not Allowed)

[RFA-AG-22-010](#) (R25 Clinical Trial Not Allowed)

Short Courses on Interdisciplinary Behavioral and Social Sciences Research on Alzheimer's Disease and Related Dementias

The goal of the FOA is to support short courses geared towards advancing selected priority topic areas identified by the NIH on Aging in order to advance behavioral and social science research on Alzheimer's disease and its related dementias (AD/ADRD). It targets the following three priority research areas: 1) cross-national dementia research using harmonized data on cognitive function; 2) behavioral economic approaches to improve AD/ADRD health care delivery at the organizational level; and 3) integrating machine learning and the social sciences to improve healthcare research in AD/ADRD.

Application Due Date: October 4, 2021.

[RFA-HL-21-014](#) (R01 Clinical Trial Optional)

Understanding and Reducing Cardiovascular Disease in Type 1 Diabetes Mellitus

This funding opportunity will support epidemiologic studies to refine risk assessment, mechanistic trials to enhance understanding of the pathophysiology of CVD in T1DM, and small clinical trials that could inform the future development of larger trials focused on preventing or reducing the CVD complications of T1DM. The overall goal is to develop evidence-based guidelines to prevent or reduce CVD complications of T1DM across the lifespan.

Application Due Date: October 15, 2021.

[RFA-DK-21-015](#) (P30 Clinical Trial Optional)

Nutrition Obesity Research Centers

This FOA invites applications from institutions/organizations that propose to establish core centers that are part of an integrated and existing program of nutrition and/or obesity research. The Nutrition Obesity Research Centers (NORC) program is designed to support and enhance the national research effort in nutrition and obesity. NORCs support three primary research-related activities: Research Core services, a Pilot and Feasibility (P and F) program, and an Enrichment program. All activities pursued by Nutrition Obesity Research Centers are designed to enhance the efficiency, productivity, effectiveness, and multidisciplinary nature of research in nutrition and obesity.

Application Due Date: October 20, 2021.

NOVEMBER DUE DATES

[RFA-AA-21-005](#) (P50 Clinical Trial Optional)

Specialized Alcohol Research Centers

The overall purpose of the NIAAA Alcohol Research Center program is to provide leadership in conducting and fostering interdisciplinary, collaborative research on a wide variety of topics relevant to the Institute's mission. These topics include, but are not limited to: the nature, etiology, genetics, diagnosis, treatment, and prevention of alcohol use disorder, alcohol-related end organ diseases and their biomedical, psychosocial, and economic consequences across the lifespan and racial/ethnic groups and other health disparity populations. **Application Due Date:** November 15, 2021.

[RFA-AA-21-006](#) (P60 Clinical trial Optional)

Comprehensive Alcohol Research Centers

The overall purpose of the NIAAA Alcohol Research Center program is to provide leadership in conducting and fostering interdisciplinary, collaborative research on a wide variety of topics relevant to the Institute's mission. These topics include, but are not limited to: the nature, etiology, genetics, diagnosis, treatment, and prevention of alcohol use disorder, alcohol-related end organ diseases and their biomedical,

psychosocial, and economic consequences across the lifespan and racial/ethnic groups and other health disparity populations. **Application Due Date:** November 15, 2021.

MULTIPLE DUE DATES

[RFA-HL-22-010 \(K01 Independent Clinical Trial Required\)](#)

[RFA-HL-22-011 \(K01 Independent Clinical Trial Not Allowed\)](#)

Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research

This FOA invites applications to enhance the pool of highly trained investigators from diverse backgrounds, including those from groups underrepresented in research areas of interest to the NHLBI. The career development will take place under the guidance of an experienced mentor in the biomedical, behavioral or clinical sciences leading to research independence. It is targeted toward individuals whose basic, clinical, and translational research interests are grounded in the advanced methods and experimental approaches needed to solve problems related to cardiovascular, pulmonary, and hematologic diseases and sleep disorders in the general and health disparities populations.

Application Due Dates: October 14, 2021; February 11, 2022; October 13, 2022; February 14, 2023; October 13, 2023; and February 13, 2024.

[RFA-HL-23-004 \(R35 Clinical Trial Optional\)](#)

NHLBI Outstanding Investigator Award (OIA)

The purpose of the NHLBI Outstanding Investigator Award (OIA) is to promote scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program Directors/Principal Investigators (PD/PIs) who are currently PD/PIs on at least two NHLBI R01-equivalent awards and whose outstanding record of research demonstrates their ability to make major contributions to heart, lung, blood and sleep (HLBS) research. The OIA is intended to support a research program, rather than a research project, by providing the primary and most likely sole source of NHLBI funding on individual grant awards. The OIA will support the research program of NHLBI-funded investigators for up to seven years. **Application Due Dates:** February 15, 2022; February 15, 2023; and February 15, 2024.

[RFA-HL-23-005 \(R35 Clinical Trial Optional\)](#)

NHLBI Emerging Investigator Award (EIA)

The purpose of the NHLBI Emerging Investigator Award (EIA) is to promote scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program Directors/Principal Investigators (PD/PIs) who are currently PD/PIs on at least two NHLBI R01-equivalent awards and whose outstanding record of research demonstrate their ability to make major contributions to heart, lung, blood and sleep (HLBS) research. The EIA will support the research program of NHLBI-funded investigators for up to seven years. **Application Due Dates:** February 15, 2022; February 15, 2023; and February 15, 2024.

[RFA-NS-20-008 \(R41/R42\)](#); [RFA-NS-20-010 \(R43/R44\)](#) clinical trial required

[RFA-NS-20-009 \(R41/R42\)](#); [RFA-NS-20-011 \(R43/R44\)](#) clinical trial not allowed

HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management

These FOAs aim to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management. They are focused on applications directed at improving pain treatment, including the development of new non-addictive medications and devices and objective pain measurement. In addition, NIH is interested in new screening tools and models focused specifically on pain and development of pain therapies. **Application Due Dates:** September 8, 2021; January 6, 2022; April 6, 2022; and September 8, 2022.

[RFA-AG-21-021](#) K76 Clinical Trial Required

Paul B. Beeson Emerging Leaders Career Development Award in Aging

This FOA invites early-stage physician and other health professional investigators with a commitment to aging and/or aging-related diseases to apply for this award to advance their research and leadership skills

in their specialty and in the broader field of aging and geriatrics research. LOI due 30 days before application due date.

Application Due Dates: October 22, 2021 and October 21, 2022.

[RFA-NS-19-043 \(K99/R00\)](#) clinical trial not allowed

[RFA-NS-19-044 \(K99/R00\)](#) independent clinical trial required

BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity

This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The BRAIN Initiative is aimed at revolutionizing our understanding of the human brain. By accelerating the development and application of innovative technologies, researchers will be able to produce a new dynamic picture of the brain that, for the first time, will show how individual cells and complex neural circuits interact in both time and space.

Application Due Dates: June 9, 2021; October 6, 2021; February 10, 2022; June 8, 2022; and October 11, 2022.

[RFA-OD-20-008 \(K01\)](#) clinical trial not allowed

[RFA-OD-20-011 \(K01\)](#) clinical trial required

Mentored Research Scientist Career Development Award in Tobacco Regulatory Research

This award provides support and protected time (2-5 years) for an intensive, supervised career development experience in biomedical, behavioral, and social science research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing and that will lead to research independence. Candidates for the K01 award must have a research or health-professional doctoral degree.

Application Due Dates: October 08, 2021 and July 8, 2022.

[RFA-OD-20-009 \(K99/R00\)](#) clinical trial not allowed

[RFA-OD-20-010 \(K99/R00\)](#) clinical trial required

Pathway to Independence Award in Tobacco Regulatory Research

This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. This program will provide independent research support during this transition in order to help awardees launch competitive, independent research careers.

Application Due Dates: October 08, 2021 and July 8, 2022.

[RFA-DA-19-019 \(R43/R44\)](#) clinical trial optional

[RFA-DA-19-020 \(R41/R42\)](#) clinical trial optional

America's Startups and Small Businesses Build Technologies to Stop the Opioid Crisis

These FOAs invite applications from US small business concerns to develop technologies to provide science-and research-based solutions to the opioid emergency. **Application Due Date:** September 8, 2022.

[RFA-ES-19-011 \(R21\)](#) – clinical trial not allowed

Mechanism for Time-Sensitive Research Opportunities in Environmental Health Sciences

This FOA supports novel environmental health research in which an unpredictable event or policy change provides a limited window of opportunity to collect human biological samples or environmental exposure data. A distinguishing feature of an appropriate study is the need for rapid review and funding, substantially shorter than the typical NIH grant review/award cycle, for the research question to be addressed and swiftly implemented. **Application Due Dates:** Monthly due dates; please refer to the RFA.

[RFA-CA-21-013](#) (R21 Clinical Trial Optional)

[RFA-CA-21-014](#) (U01 Clinical Trial Optional)

[RFA-CA-21-015](#) (U24 Clinical Trial Optional)

[RFA-CA-21-016](#) (U24 Clinical Trial Optional)

Early-Stage Development of Informatics Technologies for Cancer Research and Management

The purpose of FOA is to invite applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. This FOA focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined as initial tool development or the significant modification of existing tools for new applications.

Application Due Dates: June 8, 2021 and November 17, 2021.

[RFA-DK-20-032](#) (R34 Clinical Trial Required)

Pilot and Feasibility Studies to Facilitate the Use of Diabetes Self-Management Education and Support to Improve Diabetes Care

The FOA is to test an innovative and pragmatic approach to address barriers to and facilitate greater use of diabetes self-management education and support (DSMES) by people living with diabetes mellitus. Research applications should engage key stakeholders in cultivating a practical and sustainable strategy with the potential for dissemination. The pilot trial of the proposed strategy should be designed to generate preliminary data in support of a future, full-scale trial to study broader dissemination and implementation to expand the use of DSMES.

Application Due Dates: June 22, 2021; June 22, 2022; and June 22, 2023.

[RFA-AI-21-023](#) (R01 Clinical Trial Optional)

Respond: Epidemiology to End the HIV Epidemic (RESPOND: EEE)

The purpose of FOA is to support applications that address the RESPOND pillar of the *Ending the HIV Epidemic: A Plan for America* (EHE) initiative. The objective is to better understand HIV susceptibility and ongoing transmission in the United States (U.S.) using local and population-level epidemiology in collaboration with implementing partners. Data generated through this research will inform intervention approaches and facilitate more timely evaluation of context-specific HIV control strategies towards the goal of ending the HIV epidemic in the U.S.

Application Receipt Dates: Multiple dates, see announcement.

NIH Funding Opportunities: Program Announcements Reviewed in an Institute (PAR)

[PAR-21-168 \(R25\)](#) Clinical Trial Not Allowed

Summer Research Education Experience Program

The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. R25 programs that propose at least 8 weeks, but fewer than 15 weeks, of full-time research experiences during the summer may request continued part-time support for the participants to work on their research projects during the school year, up to the equivalent of a total of 15 weeks of full-time participation, as long as the entire research experience is completed within a 12-month period. Applications that demonstrate the potential to impact students and teachers from diverse backgrounds are particularly encouraged.

Application Due Dates: March 17, 2022; March 17, 2023; and March 19, 2024.

[PAR-20-236\(R25\)](#) Clinical Trials Not Allowed

Providing Research Education Experiences to Enhance Diversity in the Next Generation of Substance Use and Addiction Scientists

This FOA invites applications from established researchers with a record of NIH funding, who can demonstrate that they have successfully guided previous early career scientists to independent research careers and are able to direct an educational research capacity building program. This R25 program intends to strengthen the pipeline of individuals in biomedical, behavioral, and clinical substance use and addiction research across various stages of the research pipeline to enhance the number of independently funded investigators from diverse backgrounds. **Application Due Dates:** August 10, 2021; November 15, 2021; March 15, 2022; August 10, 2022; November 15, 2022; March 15, 2023; August 10, 2023; and November 15, 2023.

[PAR-20-310 \(R01\)](#) Clinical Trial Optional

Health Services Research on Minority Health and Health Disparities

The primary interest of this FOA is research on system-wide health services research that encompasses the diversity of individuals served within these health care systems. It is expected that projects will include patient or participant samples that are representative of the population served by the health care system(s) to be studied. Projects that include populations that identify across more than one health disparity group are encouraged.

Application Due Dates: November 17, 2021; March 17, 2022; November 17, 2022; and February 17, 2023.

[PAR-20-302\(R01\)](#)

[PAR-20-303 \(R21\)](#)

Tobacco Control Policies to Promote Health Equity

Specifically, this FOA aims to stimulate scientific inquiry focused on innovative state and local level tobacco prevention and control policies. The long-term goal of this FOA is to reduce disparities in tobacco-related cancers, and in doing so, to promote health equity among all populations.

Application Due Dates: [Standard dates](#) apply.

[PAR-20-289 \(R25\)](#)-Clinical Trial Not Allowed

NIAID Research Education Program

The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. The PD/PI should be an established investigator in the scientific area in which the application is targeted and capable of providing both administrative and scientific leadership to the development and implementation of the proposed program. The PD/PI will be expected to monitor and assess the program and submit all documents and reports as required. Participants are limited to the following individuals:

- Graduate/health professional (e.g., medical) students, medical residents, postdoctoral fellows, and/or early-career faculty. For this program "early career faculty" must be within the first 8 years of their first faculty appointment.
- Participants may be from a single career stage, or programs may propose to bridge several career stages of participants.
- Participants may be early career researchers that are moving into new research areas relevant to the NIAID research.

Note that high school and undergraduate students, postbaccalaureate fellows, and master's level graduate students may not be supported as participants under this FOA.

Application Due Dates: December 7, 2021 and December 7, 2022

[PAR-21-027 \(R01\)](#) Clinical Trial Not Allowed

Multidisciplinary Approaches to HIV-Associated Comorbidities and Prioritizing Intervention Targets

This FOA seeks applications for comprehensive systems biology studies using multidisciplinary team science to identify common, overlapping etiologies of HIV-associated comorbidities. Ultimately, the goal is to identify targets for intervention to mitigate multiple comorbidities associated with HIV infection.

Application Due Dates: May 7, 2021; January 7, 2022; May 7, 2022; and January 7, 2023.

[PAR-21-044 \(X01\)](#)

Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access

This Funding Opportunity Announcement (FOA) allows investigators to apply for access to the Population Assessment of Tobacco and Health (PATH) Study biospecimens for use in conducting tobacco-related research studies. The PATH Study collects data from adults and youth. Investigators proposing meritorious and feasible studies consistent with [PATH Study objectives](#) and/or research priorities for tobacco regulatory science will be given highest priority for access to PATH Study biospecimens.

Application Due Dates: October 29, 2021; April 29, 2022; October 31, 2022; April 28, 2023; and October 31, 2023.

[PAR-20-307\(P30\)](#) Clinical Trial Optional

[PAR-20-308\(P30\)](#) Clinical Trial Optional

Developmental AIDS Research Centers on Mental Health and HIV/AIDS

D-ARC awards permit the centralized coordination of affiliated research activities, foster the development of scientific innovations and new collaborations, encourage interdisciplinary research, and facilitate the dissemination of public health advances to implementing agencies, academia, affected communities, and policymakers. These Centers must have the potential to support research over a range of cross-cutting areas that may include biological, biomedical, behavioral, neuroscience, mental health, prevention, clinical sciences, and implementation science research.

Application Due Dates: August 25, 2021; August 25, 2022; and August 25, 2023.

[PAR-21-033](#) (R01 Clinical Trial Required)

National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis

The purpose of this FOA is to seek research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of the National Cancer Institute's (NCI) Division of Cancer Treatment and Diagnosis (DCTD) and the Office of HIV and AIDS Malignancies (OHAM, Office of the Director). Applicants are strongly encouraged to consult the [NCI DCTD website](#) and/or the [OHAM website](#) to learn more about the various program goals, research priorities, and strategies developed to fight cancer. Applications submitted to this FOA must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see [NOT-OD-15-015](#) for details) and provide specific clinical trial information as described in this FOA. This FOA does not accept phase III clinical trials in any area of cancer research;

Application Due Dates: Standard dates apply.

[PAR-21-035](#) (R01 Clinical Trial Required)

Cancer Prevention and Control Clinical Trials Grant Program

The National Cancer Institute (NCI) invites applications for support of investigator-initiated clinical trials related to the programmatic interests of the NCI Division of Cancer Prevention and/or the NCI Division of Cancer Control and Population Sciences that have the potential to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health. Applications submitted to this FOA must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see [NOT-OD-15-015](#) for details) and provide specific clinical trial information as described in this FOA and the application instructions.

Application Due Dates: Standard dates apply.

[PAR-21-038](#) (R01 Clinical Trial Not Allowed)

[PAR-21-039](#) (R01 Basic Experimental Studies with Humans Required)

Stephen I. Katz Early-Stage Investigator Research Project Grant

The Stephen I. Katz Early-Stage Investigator Research Project Grant supports an innovative project that represents a change in research direction for an early-stage investigator (ESI) and for which no preliminary data exist. Applications submitted to this Funding Opportunity Announcement (FOA) must not include preliminary data. Applications must include a separate attachment describing the change in research direction. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

Application Due Dates: September 28, 2021; January 26, 2022; May 26, 2022; September 27, 2022; January 26, 2023; May 26, 2023; and September 26, 2023.

[PAR-21-072](#) (R24 Clinical Trial Not Allowed)

NIAAA Resource-Related Research Projects

The purpose of the R24 grant is to support investigator-initiated resources designed to provide materials and services to support and advance biomedical research on a national basis. An R24 resource grant mechanism is a non-hypothesis-driven activity to provide data, materials, tools, or services that are essential to making timely, high quality, and cost-efficient progress in a field. Hypothesis-driven research

applications should not be submitted in response to this program announcement but to another mechanism that encourages this type of research.

Application Due Dates: Standard dates apply.

[PAR-21-077](#) (R21/R33 - Clinical Trial Not Allowed)

Exploring the Scientific Value of Existing or New Sepsis Human Biospecimen Collections

This FOA invites applicants to submit proof of concept and scale-up studies to determine the scientific value of existing or new collections of human sepsis biospecimens with associated patient health record data. The biospecimens used in this study must be linked to clinical datasets useful for sepsis endotyping/stratification and characterization of disease trajectory, and the use of contemporary cutting-edge technologies in the analysis of these biospecimens is highly encouraged. The FOA will provide support for up to two years (R21 phase) for research planning activities and feasibility studies, followed by the possible transition to up to two additional years of scaled-up, expanded, or confirmatory research support (R33 phase).

Application Due Dates: Standard dates apply

[PAR-20-315](#) (R00 Clinical Trial Optional)

Limited Competition: Lasker Clinical Research Scholars Transition Award

The Lasker Clinical Research Scholars Program supports research activities during the early-stage careers of independent clinical researchers. This FOA offers the opportunity for current Lasker awardees (Si2) to apply for the transition phase (R00) of the program. In the R00 phase, successful Si2 scholars will receive up to 5 years of NIH support for their research at an extramural research facility.

Application Due Dates: Rolling receipt dates

[PAR-21-022](#) (R01 Clinical Trial Optional)

[PAR-21-023](#) (R34 Clinical Trial Optional)

Multi-Site Studies for System-Level Implementation of Substance Use Prevention and Treatment Services

This FOA seeks research projects that will test implementation strategies intended to achieve system-wide integration of evidence-based practices (interventions, guidelines, or service delivery models) to prevent or treat substance use disorders (broadly defined to include alcohol, tobacco and other drugs, as well as prescription medications). Areas of interest also include implementation of guidelines related to the appropriate use of opioids for pain management in individuals with or at risk for opioid use disorder. When clearly justified, applicants may propose to test strategies that are designed to achieve system-wide de-implementation of programs or clinical practices that are ineffective, unproven, wasteful or harmful.

Application Due Dates: July 19, 2021; November 15, 2021; July 19, 2022; November 15, 2022; July 19, 2023; and November 15, 2023.

[PAR-21-065](#) Curriculum or Methods Development (R25 Clinical Trial Not Allowed)

[PAR-21-066](#) Courses for Skills Development (R25 Clinical Trial Not Allowed)

[PAR-21-067](#) Research Experiences (R25 Clinical Trial Not Allowed)

Cancer Research Education Grants Program

The over-arching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients.

Application Due Dates: Standard dates apply.

[PAR-21-080](#) (R01 Clinical trial not allowed)

[PAR-21-081](#) (R01 Clinical Trial Optional)

Addressing the Etiology of Health Disparities and Health Advantages Among Immigrant Populations

Addressing the Etiology of Health Disparities and Health Advantages Among Immigrant Populations

The purpose of this FOA is to support innovative research to understand factors uniquely associated with the immigration experience that contribute to health disparities or health advantages among U.S. immigrant

populations. Most research on immigrant health does not consider the factors and processes that pushed migration of members from groups or subsets of groups from one country to another. Little attention has been given to integration of the pre-existing experiences, (for example, starvation resulting from rapid environmental changes, changing food sources, exposures to toxic chemicals and pesticides), and how the experience of migration itself, or how the process of adjustment and adaptation to a new cultural, social, political and ecological environment may affect health outcomes. It is also important to consider the period(s) in the life course when immigration was experienced and how that experience may affect health outcomes.

Application Due Dates: Standard dates apply.

[PAR-21-068](#) (R01 Clinical Trial Optional)

[PAR-21-069](#) (R21 Clinical Trial Optional)

Multidisciplinary Studies of HIV/AIDS and Aging

This FOA encourages applications at the intersection of HIV and aging by addressing two overarching objectives: 1) to improve understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) to improve approaches for testing, prevention, and treatment of HIV infection, and management of HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying our current understanding of aging science.

Application Due Dates: Standard dates apply.

[PAR-21-097](#) (R34 Clinical Trial Optional)

Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders

This FOA for R34 planning grant applications focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of this FOA is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and incidence of FASD and (2) interventions for FASD. It is expected that research conducted via this mechanism will consist of studies that are a pre-requisite for preparing and submitting subsequent applications for larger scale FASD prevention or intervention studies.

Application Due Dates: October 19, 2021; February 17, 2022; June 17, 2022; October 18, 2022; February 17, 2023; June 19, 2023; and October 17, 2023.

[PAR-21-098](#) (R61/R33 Clinical Trial Optional)

Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders

This FOA focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of this FOA is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and the incidence of FASD and (2) interventions for FASD. These objectives will be accomplished with the Exploratory/Developmental Phased Award (R61/R33) mechanism, clinical trial optional. The R61 phase will support pilot studies or secondary data analysis for hypothesis development and feasibility, and research testing the hypotheses can be expanded in the R33 phase. The transition to the R33 phase will be determined by NIAAA program staff after evaluation of the achievement of specific milestones set for the R61 phase. Highest priority will be given to applications with clinical trials.

Application Due Dates: October 19, 2021; February 17, 2022; June 17, 2022; October 18, 2022; February 17, 2023; June 19, 2023; and October 17, 2023.

[PAS-21-031](#) (R01 Clinical Trial Optional)

Priority HIV/AIDS Research within the Mission of the NIDDK

This Funding Opportunity Announcement (FOA) seeks to stimulate HIV/AIDS research within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) that align with the HIV/AIDS research priorities outlined by the NIH Office of AIDS Research (OAR). These priorities were most recently described in [NOT-OD-20-018 UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding](#).

Application Due Dates: Standard dates apply.

[PAR-21-170](#) (K01 Independent Basic Experimental Studies with Humans Required)

[PAR-21-171](#) (K01 Clinical Trial Required)

[PAR-21-172](#) (K01 Clinical Trial Not Allowed)

Transition to Independent Environmental Health Research (TIEHR) Career Award

The Transition to Independent Environmental Health (TIEHR) Career Award is a 3-year bridge scholar development program for newly independent faculty who intend to pursue research careers in environmental health sciences. At the conclusion of the career development period the candidates are expected to demonstrate they can successfully compete for research funding in the environmental health sciences. **Application Due Dates:** Standard dates apply.

[PAR-21-173](#) (R16 - Clinical Trial Not Allowed)

Support for Research Excellence – First Independent Research (SuRE-First) Award

The purpose of SuRE-First awards is to support research grants for faculty investigators who have not had prior independent external research grants. Since the SuRE-First Award is structured to best support a single PD/PI, multiple PD(s)/PI(s) are not allowed. PD(s)/PI(s) with similar or complementary research interests may apply separately. A PD/PI must have a full-time tenure-track (or equivalent) faculty appointment at the applicant institution and be eligible to apply for NIH research project grants.

Application Due Dates: Standard dates apply.

[PAR-21-183](#) (UG3/UH3 Clinical Trial optional)

Developing Digital Therapeutics for Substance Use Disorders

The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development of Digital Therapeutics (DTx) to treat Substance Use Disorders (SUDs). The primary objective of this FOA is to move DTx to their next step in the development process, with the ultimate goal of generating new, FDA authorized, disseminated treatments for SUDs. Applications may focus on the pre-clinical and/or clinical development and testing of new DTx or existing DTx developed for other indications.

Open Date (Earliest Submission Date): July 04, 2021

Application Receipt Dates: Multiple dates, see announcement.

[PAR-21-206](#) (R01 Clinical Trial Optional)

Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes.

Application Receipt Dates: Multiple dates, see announcement.

[PAR-21-208](#) (R21 Clinical Trial Optional)

Cutting-Edge Basic Research Awards (CEBRA)

The proposed research should: 1. develop, and/or adapt, revolutionary techniques or methods for addiction research or that show promising future applicability to SUD research; and /or 2. test an innovative and significant hypothesis for which there are scant precedent or preliminary data and which, if confirmed, would transform current thinking. The program supports high-risk and potentially high-impact research that is underrepresented or not included in NIDA's current portfolio that has the potential to transform SUD research.

Application Receipt Dates: Multiple dates, see announcement.

[PAR-21-196](#) (R25 Independent Clinical Trial Not Allowed)

Innovative Programs to Enhance Research Training (IPERT)

The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral, and clinical research needs. this FOA will support creative educational activities with a primary focus on: ***Courses for Skills Development; Mentoring Activities.***

Application Due Dates: October 14, 2021; October 14, 2022; and October 13, 2023.

[PAR-21-197](#) (UG3/UH3 Clinical Trial Required)

NIDCR Behavioral and Social Intervention Clinical Trial Planning and Implementation Cooperative Agreement

The purpose of this Funding Opportunity Announcement (FOA) is to encourage UG3/UH3 phased cooperative agreement research applications to plan and implement behavioral and social intervention clinical trials. Studies appropriate for this announcement include clinical trials to develop and test behavior change interventions related to dental, oral, or craniofacial conditions. Awards made under this FOA will initially support a milestone-driven planning phase (UG3) for up to 2 years, with possible transition to a clinical trial implementation phase (UH3) of up to five years.

Application Due Dates: Multiple dates, see announcement.

[PAR-21-207](#) (R01 Clinical Trial Optional)

Mechanism-Focused Research to Promote Adherence to Healthful Behaviors to Prevent Mild Cognitive Impairment (MCI) and Alzheimer's Disease and Related Dementias

This FOA invites R01 applications for ancillary studies that address psychological and interpersonal mechanisms driving adherence to behavior or lifestyle change relevant to the prevention of cognitive decline, Mild Cognitive Impairment (MCI), and Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). This FOA will specifically support ancillary studies to ongoing, early- to late-stage clinical intervention trials.

Open Date (Earliest Submission Date): August 15, 2021

Application Due Dates: Multiple dates, see announcement.

NIH Funding Opportunities: Program Announcements (PA)

The following opportunities have standard due dates unless noted otherwise:

[PA-21-232](#)

Comprehensive Care for Adults with Type 2 Diabetes Mellitus from Populations with Health Disparities (R01 Clinical Trial Optional)

Expiration Date: September 08, 2024

[PA-21-180](#)

Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R34 - Clinical Trial Optional)

Expiration Date: May 08, 2024

[PA-21-205](#)

Development & Testing of Novel Interventions to improve HIV Prevention, Treatment, and Program Implementation for People Who Use Drugs (R34 Clinical Trial Required)

Expiration Date: May 08, 2024

[PA-21-164](#)

Using Innovative Digital Healthcare Solutions to Improve Quality at the Point of Care (R21/R33 - Clinical Trial Optional)

Expiration Date: July 18, 2024

[PA-21-151](#)

NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed)

Expiration Date: January 08, 2024

[PA-21-071](#)

Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)

Expiration Date: May 8, 2023

[PA-20-272](#)

Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

Expiration Date: July 24, 2023

[PA-21-047](#) Ruth L. Kirschstein National Research Service Award (NRSA) Individual Senior Fellowship (Parent F33)

[PA-21-048](#) Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent F32)

[PA-21-049](#) Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship for Students at Institutions with NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30)

[PA-21-050](#) Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship for Students at Institutions Without NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30)

[PA-21-051](#) Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31)

[PA-21-052](#) Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research (Parent F31-Diversity)

Expiration Date: September 8, 2023

[PA-21-110](#) Pilot and Feasibility Studies in Preparation for Substance Use Prevention Trials (R34 Clinical Trial Optional)

Expiration Date: May 08, 2024

Individual Actions for Sustainability

Weatherize, weatherize, weatherize.

You can make your space more energy efficient by sealing drafts and ensuring it's adequately insulated. You can also claim [federal tax credits](#) for many energy-efficiency home improvements.



For more research-related information, please visit our website at sphhp.buffalo.edu/ras